RxDoctor Payments Data

Emily Martell

Nurse Practitioner · Boston, MANPI 1508407388

Payments from drug & device makers

$2,181in general payments, 2019–2025

Across 91 payments — averaging $23.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dexcom, Inc.$547
  • Lilly USA, LLC$419
  • Novo Nordisk$335
  • Abbott$300
  • Amgen$151
  • Sanofi-aventis U.S. LLC$120
  • plus $309 from 8 others

What the payments were for

  • Food & beverage$2,181100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,181 in reported general payments places this provider in the 95th percentile of 3,855 nurse practitioner providers in Massachusetts.

See all nurse practitioner providers in Massachusetts

Medicare billing

Part B allowed, 2024
$4,408
Medicare patients
36
Services billed
57

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide59$57,350
MounjaroTirzepatide47$52,682
TrulicityDulaglutide32$38,691
JardianceEmpagliflozin45$31,289
Lantus SolostarInsulin Glargine,hum.Rec.Anlog29$5,034
Humalog Kwikpen U-100Insulin Lispro25$3,656
Novolog FlexpenInsulin Aspart11$1,984
Nano 2nd Gen Pen NeedlePen Needle, Diabetic21$1,783
Levothyroxine Sodium88$1,123
Ultra-Fine Short Pen NeedlePen Needle, Diabetic15$975
SynthroidLevothyroxine Sodium17$810
Metformin Hcl20$267
Alendronate Sodium34$233
Atorvastatin Calcium25$160
Methimazole20$119

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$419$91,37379 claims
Novo NordiskOzempic$335$57,35059 claims
AbbVieSynthroid$85$81017 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,855 nurse practitioner providers in Massachusetts.

Other nurse practitioner in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →